Flag of the European Union EU Clinical Trials Register Help

Clinical trials for glioblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    235 result(s) found for: glioblastoma. Displaying page 11 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2020-005429-10 Sponsor Protocol Number: EORTC-1926-BTG Start Date*: 2022-03-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer EORTC
    Full Title: Romiplostim for thrombocytopenia induced by lomustine at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study
    Medical condition: thrombocytopenia caused by chemotherapy drug lomustine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001600-40 Sponsor Protocol Number: D2401GBM2 Start Date*: 2016-09-02
    Sponsor Name:Clínica Universidad de Navarra
    Full Title: Phase II randomized trial of DNX-2401 oncolytic adenovirus added to standard of care for newly diagnosed glioblastoma
    Medical condition: Multiforme Glioblastom (MGB) is the more common malignant brain tumor, with an incidence around 4 cases per 100.000 hab/year.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10029110 Neoplasms of unspecified nature LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004053-91 Sponsor Protocol Number: CO19/121741 Start Date*: 2020-07-06
    Sponsor Name:University of Leeds
    Full Title: Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
    Medical condition: Recurrent Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003513-14 Sponsor Protocol Number: DC1 Start Date*: 2009-05-20
    Sponsor Name:Department of Neurology, Karolinska University Hospital [...]
    1. Department of Neurology, Karolinska University Hospital
    2. Dept. of Pediatric hematology and oncology, Astrid Lindgren Children´s Hosp,Karolinska Univ Hospital
    Full Title: Imune therapy of High Grade Glioma with dendritic cell vaccination. A phase II study.
    Medical condition: High grade glioma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000885-13 Sponsor Protocol Number: UC-0105/1303 Start Date*: 2013-07-31
    Sponsor Name:UNICANCER
    Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug
    Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002227 Anaplastic large cell lymphoma T- and-cell types PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067917 Inflammatory myofibroblastic tumour PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024658 Liver carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003835-18 Sponsor Protocol Number: GE-135-004 Start Date*: 2009-04-21
    Sponsor Name:GE Healthcare Ltd
    Full Title: A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 ...
    Medical condition: Adult subjects with solid primary or metastatic tumours 2 cm or more in diameter. Malignancies may include but are not limited to non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), gl...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001488-10 Sponsor Protocol Number: APHP200080 Start Date*: 2020-10-05
    Sponsor Name:Assistance Publique Hopitaux de Paris
    Full Title: Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening
    Medical condition: Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection , and for the standard of care including concurrent temoradiation and adjuvant T...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011878-15 Sponsor Protocol Number: 3160A6-2208-WW Start Date*: 2009-08-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer.
    Medical condition: Solid tumor and ErbB2 negative locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) BE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005573-21 Sponsor Protocol Number: GLIOMARK1 Start Date*: 2016-04-26
    Sponsor Name:pro-ACTINA S.A.
    Full Title: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis
    Medical condition: Patients with high grade brain tumors
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001834-16 Sponsor Protocol Number: AD101_01 Start Date*: 2014-01-10
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: EVALUATION OF SEIZURE CONTROL AND QUALITY OF LIFE IN PATIENTS WITH BRAIN TUMOR RELATED EPILEPSY TREATED WITH LACOSAMIDE AS ADD-ON THERAPY: A PROSPECTIVE EXPLORATIVE STUDY
    Medical condition: PATIENTS WITH BRAIN TUMOR RELATED EPILEPSY
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10068330 Symptomatic epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018447-34 Sponsor Protocol Number: 06MH34 Start Date*: 2011-09-22
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Investigation of dendritic cell vaccine immunotherapy in paediatric high grade glioma
    Medical condition: Paediatric High grade glioma, excluding brain stem gliomas
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004740-24 Sponsor Protocol Number: INCB54828-209 Start Date*: 2022-06-29
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System ...
    Medical condition: Participants at least 18 years of age who have recurrent GBM or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors, harboring an FGFR1-3 mutation or fus...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) DK (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004213-13 Sponsor Protocol Number: ST101-101 Start Date*: 2020-07-13
    Sponsor Name:Sapience Therapeutics, Inc.
    Full Title: A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
    Medical condition: Castrate-Resistant Prostate Cancer, HR Positive local advanced/metastatic Breast Cancer, Glioblastoma, and Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-024107-27 Sponsor Protocol Number: GlioAvIr1 Start Date*: 2011-05-25
    Sponsor Name:Zentrum für Neuro-Onkologie
    Full Title: Monozentrische Randomisierte Phase III Studie zum Vergleich von hoch dosiertem Bevacizumab plus Irinotecan, niedrig dosiertem Bevacizumab plus Irinotecan und CCNU/Procarbacin bei Patienten mit fort...
    Medical condition: Patienten, die an einem Glioblastom (Glioblastoma multiforme WHO Grad IV) erkrankt sind
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001672-42 Sponsor Protocol Number: 0627-19 Start Date*: 2021-03-26
    Sponsor Name:Intas Pharmaceuticals Ltd
    Full Title: A Multicentre, Open Label, Balanced, Randomized, Single-Dose, Two-Stage, Two-Treatment, Two-Period, Two-Sequence, Two-Way, Cross-Over Study To Evaluate Comparative Bioavailability Of Temozolomide P...
    Medical condition: Patients of malignant gliomas under-going treatment with temozolomide under fasting conditions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-004558-24 Sponsor Protocol Number: CC-115-ST-001 Start Date*: 2012-06-29
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINIS...
    Medical condition: Subjects with advanced solid tumors, non-hodgkin lymphoma (NHL) and multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001881-18 Sponsor Protocol Number: CAUR85U7 Start Date*: 2006-07-14
    Sponsor Name:Fundación General Universidad Autónoma de Madrid
    Full Title: Estudio piloto fase II no controlado y multicéntrico para evaluar la eficacia y seguridad de la combinación de cetuximab (Erbitux®) y temozolamida como tratamiento de inducción seguido de radiotera...
    Medical condition: glioma maligno supratentorial de nuevo diagnóstico irresecable o con resección macroscópica incompleta
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015852-11 Sponsor Protocol Number: TC-FMISO-PET-06-1413 Start Date*: 2012-02-03
    Sponsor Name:Hospital Universitario Dr. Negrin
    Full Title: 18F-FMISO-PET in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation
    Medical condition: Hypoxia in malignant brain tumors: high grade gliomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021613-23 Sponsor Protocol Number: Start Date*: 2010-11-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy
    Medical condition: Hypertension induced by pazopanib treatment of various cancer types
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Sep 05 21:21:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA